3 Fermentation Ingredients Maker, Respiratory Medicines Leader and Chronic Therapy Brand Owner Stocks With a Strong Future Roadmap: Concord Biotech, Cipla and Torrent Pharmaceuticals

Fermentation, respiratory and chronic pharma offer a focused view of a sector where demand keeps widening. Concord Biotech, Cipla and Torrent Pharmaceuticals cover a fermentation ingredients maker, a respiratory medicines leader and a chronic therapy brand owner.

This list covers three fermentation, respiratory and chronic pharma with complete current figures: Concord Biotech, Cipla and Torrent Pharmaceuticals. Every figure comes from the latest reported financials and the 27 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Fermentation, Respiratory and Chronic Pharma?

Fermentation, respiratory and chronic pharma are listed pharmaceutical companies that make fermentation-based active ingredients, sell respiratory and anti-infective medicines and lead in heart, nervous system and stomach therapies. Their earnings depend on launches, brand strength and export demand.

Fermentation, Respiratory and Chronic Pharma at a Glance

On valuation, Cipla trades at a P/E below the industry P/E, while Concord Biotech and Torrent Pharmaceuticals trade above it, which reflects the growth the market already expects. Readers comparing fermentation, respiratory and chronic pharma should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Fermentation, Respiratory and Chronic Pharma Have a Strong Roadmap in India?

Fermentation, respiratory and chronic pharma have a strong roadmap in India because rising healthcare spending, chronic disease treatment and global demand for specialised ingredients keep widening the market for Indian pharmaceutical firms.

• Specialised ingredients. Global drug makers source complex inputs.
• Respiratory care. Inhalers and anti-infectives see steady use.
• Chronic therapies. Long-term treatment supports repeat sales.

Why Concord Biotech Features Among These Fermentation, Respiratory and Chronic Pharma

Among the fermentation, respiratory and chronic pharma on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.

Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%.

In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.

Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What to watch: Monitor the pace of new product introductions and the contribution from formulations.

Why Cipla Features Among These Fermentation, Respiratory and Chronic Pharma

Among the biopharma ingredient and respiratory medicine shares on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.

In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%.

Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.

Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

What to watch: Follow new product launches in the United States and the growth of key domestic brands.

Why Torrent Pharmaceuticals Features Among These Fermentation, Respiratory and Chronic Pharma

Among the three companies on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Concord Biotech vs Cipla vs Torrent Pharmaceuticals on Key Financials

The table below sets the three fermentation, respiratory and chronic pharma side by side on revenue, profit and margin, using reported figures.

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Torrent Pharmaceuticals shows the fastest revenue growth with a 12.4% compound annual rate. A useful habit with fermentation, respiratory and chronic pharma is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Fermentation, Respiratory and Chronic Pharma

Every theme carries risks that deserve a check before any decision. For these fermentation, respiratory and chronic pharma, the main points are: Long-term biopharma ingredient and respiratory medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Pricing pressure. Generic prices can change by market.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter fermentation, respiratory and chronic pharma by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Fermentation, Respiratory and Chronic Pharma

Fermentation, respiratory and chronic pharma reward patient research into demand, execution and financial strength. Concord Biotech, Cipla and Torrent Pharmaceuticals each have a clear plan to grow. Based on the 27 October 2026 close, Concord Biotech trades at Rs 1,375.3, Cipla at Rs 1,350 and Torrent Pharmaceuticals at Rs 4,625. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these fermentation, respiratory and chronic pharma to a watchlist.

Download the Univest iOS App or Univest Android App to track fermentation, respiratory and chronic pharma, set price alerts and get research-backed stock ideas.

What are fermentation, respiratory and chronic pharma?

Ans. Fermentation, respiratory and chronic pharma are listed pharmaceutical companies that make fermentation-based active ingredients, sell respiratory and anti-infective medicines and lead in heart, nervous system and stomach therapies. Their earnings depend on launches, brand strength and export demand. This list looks at three of them, Concord Biotech, Cipla and Torrent Pharmaceuticals, using reported FY22 to FY26 financials and the 27 October 2026 closing prices.

Which fermentation, respiratory and chronic pharma are covered in this list?

Ans. This list covers Concord Biotech, Cipla and Torrent Pharmaceuticals. Based on the 27 October 2026 close, Concord Biotech traded at Rs 1,375.3, Cipla at Rs 1,350 and Torrent Pharmaceuticals at Rs 4,625. Their return on equity ranges from 11.3% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 12.4%.

Why do fermentation, respiratory and chronic pharma have a strong future roadmap in India?

Ans. Fermentation, respiratory and chronic pharma have a strong roadmap in India because rising healthcare spending, chronic disease treatment and global demand for specialised ingredients keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Specialised ingredients. Global drug makers source complex inputs. Respiratory care. Inhalers and anti-infectives see steady use. Chronic therapies. Long-term treatment supports repeat sales. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Concord Biotech performed financially?

Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

How has Cipla performed financially?

Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What risks should investors check before buying fermentation, respiratory and chronic pharma?

Ans. Investors should check a few risks before buying fermentation, respiratory and chronic pharma. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of fermentation, respiratory and chronic pharma investment advice?

Ans. No. This article is educational and uses publicly available data as of the 27 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.